Sentiment Change Report: Agios Pharmaceuticals Inc (NASDAQ:AGIO)

April 16, 2018 - By Nellie Frank

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Logo

Sentiment for Agios Pharmaceuticals Inc (NASDAQ:AGIO)

Agios Pharmaceuticals Inc (NASDAQ:AGIO) institutional sentiment increased to 1.22 in 2017 Q4. Its up 0.01, from 1.21 in 2017Q3. The ratio is more positive, as 82 funds started new and increased holdings, while 67 sold and trimmed holdings in Agios Pharmaceuticals Inc. The funds in our partner’s database now hold: 45.70 million shares, up from 44.69 million shares in 2017Q3. Also, the number of funds holding Agios Pharmaceuticals Inc in their top 10 holdings decreased from 2 to 0 for a decrease of 2. Sold All: 19 Reduced: 48 Increased: 55 New Position: 27.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $5.00 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

The stock decreased 0.07% or $0.06 during the last trading session, reaching $87.27. About 145,345 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 41.40% since April 16, 2017 and is uptrending. It has outperformed by 29.85% the S&P500.

Analysts await Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report earnings on May, 3. They expect $-1.60 EPS, down 2.56 % or $0.04 from last year’s $-1.56 per share. After $-1.81 actual EPS reported by Agios Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -11.60 % EPS growth.

Bb Biotech Ag holds 4.38% of its portfolio in Agios Pharmaceuticals, Inc. for 2.72 million shares. Opaleye Management Inc. owns 130,000 shares or 2.38% of their US portfolio. Moreover, Opus Point Partners Management Llc has 1.42% invested in the company for 28,704 shares. The Massachusetts-based Fernwood Investment Management Llc has invested 0.84% in the stock. Rhenman & Partners Asset Management Ab, a Sweden-based fund reported 100,000 shares.#img1#

Since January 1, 0001, it had 1 buy, and 19 insider sales for $16.87 million activity.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Coverage

Ratings analysis reveals 100% of Agios Pharmaceuticals’s analysts are positive. Out of 4 Wall Street analysts rating Agios Pharmaceuticals, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $66 while the high is $95. The stock’s average target of $87 is -0.31% below today’s ($87.27) share price. AGIO was included in 7 notes of analysts from November 2, 2017. The rating was maintained by Credit Suisse on Thursday, November 2 with “Outperform”. SunTrust maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Sunday, November 19 with “Buy” rating. RBC Capital Markets maintained the stock with “Buy” rating in Wednesday, February 14 report. RBC Capital Markets maintained the shares of AGIO in report on Wednesday, November 1 with “Buy” rating. As per Thursday, February 15, the company rating was maintained by JP Morgan. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has “Outperform” rating given on Wednesday, April 11 by Credit Suisse. Credit Suisse maintained it with “Buy” rating and $80.0 target in Thursday, February 15 report.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.